Additionally, evidence showed that imatinib might play its potentially antiviral and beneficial immunomodulatory role in severe COVID-19 patients.[82] These results further support those of previous studies.[25,83] Collectively, the present findings indicate that the small-molecule protein kinase inhibitors provide a new, and perhaps superior, avenue for the severe COVID-19 treatment. Here, WEE1 is linked to COVID-19.